SP-0434: Adaptive radiation therapy by the example of head and neck cancer: is there any role for a RTT?  by Speleers, B. et al.
ESTRO 35 2016                                                                                                                                                    S203 
______________________________________________________________________________________________________ 
studies use local institutional approaches to manage imaging 
information for these purposes?  
All these issues need to be resolved before widespread 
implementation into clinical practice can take place. 
Molecular and functional imaging and its evaluation has to be 
validated and proven to be useful in multicenter studies. 
Advanced solutions need to be established to incorporate 
multiparameter information from e.g. tumor biopsy 
immunohistochemical analysis and gene-arrays into decision-
making processes for specific imaging modalities, 
individualized treatment and treatment evaluation pathways. 
The first multicenter studies with these goals in mind are 
now being established. 
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Changes in the tumoras well as normal tissues and organs 
surrounding the tumor during and/or in response to radiation 
therapy require treatmentadaptation. A need for adaptive 
radiation therapy (ART) is not obvious for alltumors, but 
head-and-neck cancer, for which substantial changes in 
tumor andparotid gland geometry and dosimetry have been 
shown [1]. Moreover, biologicchanges in the tumor may 
require treatment adaptationas well [2]. Logistics of ARTis 
complex and hampered by a lack of personnel and robust 
technical tools. Theworkflow is usually not well-defined and 
well-supported by commercial oncologyinformation and 
treatment planning systems. Nevertheless, an increasing 
numberof academic centers introduce ART in their practice 
as has done it inDepartment of Radiotherapy, Ghent 
University Hospital. In this talk theworkflow of ART for head-
and-neck cancer on the example of this particularcenter will 
be discussed in more detail including the roles of personnel 
withemphasis on RTTs, their current responsibilities and their 
possible empowermentin the frame of ART.  
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In the ARTForce project, two international clinical trials are 
conducted. The first trial (NCT01504815) for locally advanced 
head-and-neck cancer patients is a phase two trial 
randomizing between standard chemo-radiotherapy, 
redistributing the dose in the PTV of the primary tumor. 
Instead of a homogeneous dose of 70Gy in 35 fractions, an 
inhomogeneous dose is optimized based with a minimum dose 
of 64 Gy at the edge of the PTV and a maximum dose of 84 
Gy around the FDG PET SUVmax location. Additionally, in the 
experimental arm, the treatment plan is adapted after two 
weeks to account for anatomical changes. The second phase 
2 trial (NCT01024829) for locally advanced lung cancer 
patients randomizes between dose escalation to the primary 
tumor >= 72 Gy in 24 fractions and dose escalation to the 
region of the tumor defined by the 50% of FDG PET SUVmax. 
Both treatment plans are optimized to have an equal mean 
lung dose. In this presentation, dosimetric differences 
between the arms in both trials will be discussed as well as 
the impact of anatomical changes on the delivered dose and 
the effectiveness of replanning to mitigate dose 
discrepancies. 
 
Symposium: Secondary cancer after radiotherapy: from 
cancer registries to clinical implications  
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Second cancers are an important cause of morbidity and 
mortality in cancer survivors. One in five cancers diagnosed 
in the US are now second cancers. The causes of second 
cancers include lifestyle factors, genetic predisposition and 
also the treatment for the first cancer, including 
radiotherapy. In the last decade there have been a large 
number of new studies that have advanced our understanding 
of the risk of second cancers after radiotherapy. The most 
informative studies provide dose-response relationships based 
on individual dose-reconstruction. These studies suggest that 
the second cancer risk generally increases linearly with dose, 
even at organ doses of ≥60Gy. This is contrary to earlier 
theories that the dose-response would flatten or even have a 
down-turn at higher doses because of cell killing. The 
magnitude of the risk from these fractionated high-dose 
exposures is, however, 5-10 times lower than the risk from 
acute exposures of <2Gy among the Japanese atomic bomb 
survivors. The results from these detailed observational 
studies provide insights into radiation carcinogenesis from 
fractionated high-dose exposures, and can be used to develop 
second solid cancer risk projection models for newer 
radiotherapy techniques. 
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In developed countries, more than half of all cancer patients 
receive radiotherapy at some stage in the management of 
their disease. However, a radiation-induced secondary 
malignancy can be the price of success if the primary cancer 
is cured or at least controlled. Therefore, there is increasing 
concern regarding radiation-related second cancer risks in 
long-term radiotherapy survivors and a corresponding need to 
be able to predict cancer risks at high radiation doses. Of 
particular interest are second cancer risk estimates for new 
radiation treatment modalities such as intensity modulated 
radiotherapy, intensity modulated arc-therapy, proton and 
heavy ion radiotherapy. The long term risks from such 
modern radiotherapy treatment techniques have not yet 
been determined and are unlikely to become apparent for 
many years, due to the long latency time for solid tumor 
induction. Most information on the dose-response of 
radiation-induced cancer is derived from data on the A-bomb 
survivors who were exposed to gamma-rays and neutrons. 
Since, for radiation protection purposes, the dose span of 
main interest is between zero and one Gy, the analysis of the 
A-bomb survivors is usually focused on this range. With 
increasing cure rates, estimates of cancer risk for doses 
larger than one Gy are becoming more important for 
